1-(5-aminopyrimidin-2-yl)azetidin-3-ol | 1445153-73-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(5-aminopyrimidin-2-yl)azetidin-3-ol
• 英文别名: 1-(5-Aminopyrimidin-2-yl)azetidin-3-ol
• CAS: 1445153-73-0
• 化学式: C₇H₁₀N₄O
• 分子量: 166.183
• InChiKey: OHAJWYGFANPSBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(5-aminopyrimidin-2-yl)azetidin-3-ol 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl)-3-(2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)urea
  参考文献：
  名称：

  [EN] UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER
  [FR] DÉRIVÉS D'URÉE POUVANT ÊTRE UTILISÉS POUR TRAITER LE CANCER

  摘要：

  This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2022265993A1
• 作为产物：
  描述：

  1-(5-硝基嘧啶-2-基)氮杂环丁烷-3-醇 在 钯 molecular hydrogen 、 钯 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以to give crude (ii) as a yellow oil (104 mg)的产率得到1-(5-aminopyrimidin-2-yl)azetidin-3-ol
  参考文献：
  名称：

  HETEROCYCLIC UREA COMPOUNDS

  摘要：

  本发明提供了以下式子的化合物，它们的外消旋体、对映体和盐。同时，还提供了这些化合物作为抗菌剂的用途、包含它们的组成物以及它们的制造过程。

  公开号：

  US20140323486A1

文献信息

• [EN] HETEROCYCLIC UREA COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'URÉE
  申请人：BIOTA EUROPE LTD

  公开号：WO2013091011A1

  公开（公告）日：2013-06-27

  The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供了以下式的化合物，它们的外消旋体、对映体和盐。还提供了这些化合物作为抗菌剂的用途，包括它们的组合物和制造过程。
• Heterocyclic urea compounds
  申请人：BIOTA EUROPE LTD

  公开号：US09060515B2

  公开（公告）日：2015-06-23

  The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供以下公式的化合物，外消旋体，对映体和其盐。还提供这些化合物作为抗菌剂的用途，包含它们的组合物和制造它们的过程。
• US9060515B2
  申请人：——

  公开号：US9060515B2

  公开（公告）日：2015-06-23
• HETEROCYCLIC UREA COMPOUNDS
  申请人：BIOTA EUROPE LTD

  公开号：US20140323486A1

  公开（公告）日：2014-10-30

  The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

  本发明提供了以下式子的化合物，它们的外消旋体、对映体和盐。同时，还提供了这些化合物作为抗菌剂的用途、包含它们的组成物以及它们的制造过程。
• [EN] UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER<br/>[FR] DÉRIVÉS D'URÉE POUVANT ÊTRE UTILISÉS POUR TRAITER LE CANCER
  申请人：[en]SCORPION THERAPEUTICS, INC.

  公开号：WO2022265993A1

  公开（公告）日：2022-12-22

  This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.